Award
National Cancer Institute 11192259
Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemia
Recipient
National Cancer Institute (NCI)
Award Amount
$733,489.00
Ceiling
$733,489.00
Awarded
September 15, 2025
Identifier
11192259
This award funds research on the role of KAT6A in MLL-rearranged acute myeloid leukemia, aiming to identify therapeutic targets and test inhibitors using various experimental models.
Description
The project focuses on the molecular mechanisms of KAT6A and ENL in AML. The project involves in vitro, in vivo, and clinical sample testing. The funding is from the NIH/NCI under PA-20-185. The project aims to identify therapeutic targets and test inhibitors in mouse models and patient samples.